BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 19507240)

  • 21. Non-naturally Occurring Helical Molecules Can Interfere with p53-MDM2 and p53-MDMX Protein-Protein Interactions.
    Su A; Wang S; Sada A; Otani Y; Zhai L; Liu X; Sayama M; Ohki R; Ohwada T
    Chem Pharm Bull (Tokyo); 2019; 67(10):1139-1143. PubMed ID: 31582633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX.
    Uldrijan S; Pannekoek WJ; Vousden KH
    EMBO J; 2007 Jan; 26(1):102-12. PubMed ID: 17159902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
    Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
    Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
    Popowicz GM; Czarna A; Holak TA
    Cell Cycle; 2008 Aug; 7(15):2441-3. PubMed ID: 18677113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73.
    Zdzalik M; Pustelny K; Kedracka-Krok S; Huben K; Pecak A; Wladyka B; Jankowski S; Dubin A; Potempa J; Dubin G
    Cell Cycle; 2010 Nov; 9(22):4584-91. PubMed ID: 21088494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
    Phan J; Li Z; Kasprzak A; Li B; Sebti S; Guida W; Schönbrunn E; Chen J
    J Biol Chem; 2010 Jan; 285(3):2174-83. PubMed ID: 19910468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
    Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations.
    Chen J; Zhang D; Zhang Y; Li G
    Int J Mol Sci; 2012; 13(2):2176-2195. PubMed ID: 22408446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization.
    Graves B; Thompson T; Xia M; Janson C; Lukacs C; Deo D; Di Lello P; Fry D; Garvie C; Huang KS; Gao L; Tovar C; Lovey A; Wanner J; Vassilev LT
    Proc Natl Acad Sci U S A; 2012 Jul; 109(29):11788-93. PubMed ID: 22745160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular investigation of the dual inhibition mechanism for targeted P53 regulator MDM2/MDMX inhibitors.
    Zhao X; Xiong D; Luo S; Duan L
    Phys Chem Chem Phys; 2022 Jul; 24(27):16799-16815. PubMed ID: 35775962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural basis of how stress-induced MDMX phosphorylation activates p53.
    Chen X; Gohain N; Zhan C; Lu WY; Pazgier M; Lu W
    Oncogene; 2016 Apr; 35(15):1919-25. PubMed ID: 26148237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revealing binding selectivity of ligands toward murine double minute 2 and murine double minute X based on molecular dynamics simulations and binding free energy calculations.
    Shi S; Sui K; Liu W; Lei Y; Zhang S; Zhang Q
    J Biomol Struct Dyn; 2020 Oct; 38(17):5081-5094. PubMed ID: 31755361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.
    Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS
    Cell Cycle; 2010 Mar; 9(6):1167-81. PubMed ID: 20190571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
    Uhrinova S; Uhrin D; Powers H; Watt K; Zheleva D; Fischer P; McInnes C; Barlow PN
    J Mol Biol; 2005 Jul; 350(3):587-98. PubMed ID: 15953616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative study of the p53-mdm2 and p53-MDMX interfaces.
    Böttger V; Böttger A; Garcia-Echeverria C; Ramos YF; van der Eb AJ; Jochemsen AG; Lane DP
    Oncogene; 1999 Jan; 18(1):189-99. PubMed ID: 9926934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes.
    Kallen J; Goepfert A; Blechschmidt A; Izaac A; Geiser M; Tavares G; Ramage P; Furet P; Masuya K; Lisztwan J
    J Biol Chem; 2009 Mar; 284(13):8812-21. PubMed ID: 19153082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MDM2 interacts with MDMX through their RING finger domains.
    Tanimura S; Ohtsuka S; Mitsui K; Shirouzu K; Yoshimura A; Ohtsubo M
    FEBS Lett; 1999 Mar; 447(1):5-9. PubMed ID: 10218570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MDMX: a novel p53-binding protein with some functional properties of MDM2.
    Shvarts A; Steegenga WT; Riteco N; van Laar T; Dekker P; Bazuine M; van Ham RC; van der Houven van Oordt W; Hateboer G; van der Eb AJ; Jochemsen AG
    EMBO J; 1996 Oct; 15(19):5349-57. PubMed ID: 8895579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
    Zaytsev A; Dodd B; Magnani M; Ghiron C; Golding BT; Griffin RJ; Liu J; Lu X; Micco I; Newell DR; Padova A; Robertson G; Lunec J; Hardcastle IR
    Chem Biol Drug Des; 2015 Aug; 86(2):180-9. PubMed ID: 25388787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 Phosphomimetics Preserve Transient Secondary Structure but Reduce Binding to Mdm2 and MdmX.
    Levy R; Gregory E; Borcherds W; Daughdrill G
    Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30832340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.